Loading…
← CockpitCompetitor Analysis › 301047.SZ Sino Biological Inc. Class AOpen in the cockpit ↗

Sino Biological Inc. Class A301047.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese life-science reagent supplier making recombinant proteins and antibodies for biopharma R&D, diagnostics and vaccine development.

≈ A Chinese Bio-Techne/R&D SystemsMomentum strong 74
Mkt cap
$1.60B
US dollars, full cap
Free float
64%
of shares outstanding
$/day
$134M
20-day average traded
Fwd P/E
51.6×
forward earnings
ROIC−WACC
-4.1 pp
WACC 11.0%
Hurdle
+46 pp
Req g minus delivered
Next earnings
152 days
19 Apr 2027
Close · CNYCN¥87.67
1D-1.8%
1W-22.7%
1M-22.3%
3M-26.9%
6M+26.9%
YTD+29.7%
1Y+15.1%
ATR %11.3%
52w lowhigh46.9% off high

What Sino Biological does

Chinese life-science reagent supplier making recombinant proteins and antibodies for biopharma R&D, diagnostics and vaccine development.

Sells research-grade proteins and antibodies from a catalogue in small lots to labs, and also does contract research and manufacturing work for drug developers. Product sales carry the company, and a large share goes to customers abroad. Demand rose sharply with vaccine and diagnostic research during COVID.

In one line: A Chinese Bio-Techne/R&D Systems.

Products and services

  • Recombinant proteins
  • Research antibodies
  • CRO/CDMO bioprocessing services

Customers

  • Biopharma and biotech R&D labs
  • Diagnostic/vaccine developers

Where it sits in the supply chain

  • Health Care
  • Life-science tools
  • Recombinant protein/antibody reagents

What could go right

  • Global biopharma R&D spending growth

What could go wrong

  • Biotech-funding cycle sensitivity
  • Competition from global life-science tool vendors

Moat: narrow (scale, process know-how, installed base). Broad, validated catalog of research-grade proteins used across many biopharma R&D pipelines.

Headquarters: Beijing, China · Founded: 2009 · Employees: 1,069

Named competitors

Sino Biological at a glance

Size Sino Biological (301047.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.60B, the 1426th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥87.67 on 18 Nov 2026.

Performance Over six months the shares gained 26.9%, against -9.1% for the median peer and -20.0% for the China market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth Revenue grew 20.0% over the last twelve months (peer median +6.6%); the operating margin is 16.8% (peer median 12.0%).

Valuation It trades at 51.6× forward earnings against a peer median of 23.8× (2nd most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is -15%, so the hurdle is +46 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.1 points below its cost of capital (11.0% WACC).

Next results Next results expected around 19 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026301047.SZ 129Peer median 92
Six months, rebased to 100: Sino Biological against the median of its 20 peers (local-currency closes).

Sino Biological financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥792MCN¥694MCN¥614MCN¥646MCN¥568M
Revenue growth—+13%-5%+14%—
Gross profitCN¥618MCN¥448MCN¥389MCN¥481MCN¥455M
EBITDAn/aCN¥191MCN¥130MCN¥213MCN¥247M
Net incomeCN¥179MCN¥148MCN¥122MCN¥260MCN¥303M
Free cash flowCN¥120MCN¥122MCN¥130M-CN¥645MCN¥205M
Capital expenditureCN¥159MCN¥101MCN¥69.9MCN¥1.04BCN¥156M
Total debtCN¥41.1MCN¥53.5MCN¥67.4MCN¥85.1MCN¥70.5M

Quarterly statements and history in the cockpit →

Sino Biological competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-20%0%+20%002755600420ANURASJUBLPHARMA002675ASTRAZEN000766002019SRPT1681300357600572603235INDGN600993298380CAPLIPOINT300723FAE301047.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Sino Biological is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×60×002755600420ANURASJUBLPHARMA0026750020191681300357600572INDGN600993CAPLIPOINT300723FAE301047.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sino Biological is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%002755600420002675ASTRAZEN000766SRPT1681300357600572603235INDGN600993CAPLIPOINT300723FAE301047.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sino Biological is the large dot.

Sino Biological competitors and peer comparison

Head to head with its named competitors (301047.SZ vs 301080.SZ vs TECH vs TMO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sino Biological 301047.SZ$1.60B+27%+20%17%51.6×31.1%
Acrobiosystems 301080.SZ$2.31B+65%+29%17%55.2×41.3%
Bio-Techne TECH$11.4B+56%+1%21%34.4×31.6%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%

How Sino Biological compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sino Biological against its 20 peers (data as of 18 Nov 2026)
Measure301047.SZPeer medianRank in peer set
1-month return-22.3%-3.8%2nd lowest of 21
6-month return+26.9%-9.1%2nd highest of 20
Distance from 52-week high-46.9%-29.4%4th lowest of 21
Revenue growth (TTM)+20.0%+6.6%5th highest of 20
Operating margin16.8%12.0%5th highest of 20
Forward P/E51.6×23.8×2nd most expensive of 15
Growth the price implies (Req g, 7 yrs)31.1%6.0%4th most demanding of 16
Growth delivered (Del g)-15.1%+6.8%lowest of 16
Hurdle (Req g minus delivered)+46.2 pp+2.0 ppmost demanding of 16
ROIC minus cost of capital-4.1 pp+1.2 pp7th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sino Biological 301047.SZChina$1.60B+27%+20%17%51.6×31.1%-15.1%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%57.4×12.8%-14.0%
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%12.6×-6.6%-5.6%
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%49.9×n/an/a
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%29.0×n/an/a
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%47.2×6.0%-4.3%
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%n/a42.4%+23.0%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%25.6×n/an/a
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%n/a-6.8%+32.4%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%16.0×-6.1%+1.9%
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%n/a-4.9%+0.2%
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%n/an/an/a
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%

Questions

Who are Sino Biological's main competitors?
Named competitors: Acrobiosystems (301080.SZ), Bio-Techne (TECH), Thermo Fisher Scientific (TMO). The cockpit's measured peer set (industry) also includes Beijing Aosaikang Pharmaceutical (002755.SZ), Shanghai Shyndec Pharmaceutical (600420.SS), Anupam Rasayan India (ANURAS.NS), Jubilant Pharmova (JUBLPHARMA.NS), Yantai Dongcheng Biochemicals (002675.SZ), AstraZeneca Pharma India (ASTRAZEN.NS).
Is Sino Biological expensive compared with its peers?
On forward p/e it trades at 51.6× against a peer median of 23.8×, 2nd most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is -15%, so the hurdle is +46 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Sino Biological stock performed?
Over six months to 18 Nov 2026 the shares returned +26.9% against -9.1% for the median peer; over one year +15.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.